{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T21:59:52Z","timestamp":1776722392611,"version":"3.51.2"},"reference-count":16,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cutaneous adverse drug reactions due to antipsychotic therapy are well-documented, although their manifestations are highly variable. Blonanserin, a second-generation antipsychotic, is generally considered to have a favorable tolerability profile. Cutaneous reactions to blonanserin are rare and, more importantly, remain poorly characterized. This case report describes a novel and distinctive presentation of a bilateral hand-restricted drug eruption attributed to blonanserin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case Summary<\/jats:title>\n                    <jats:p>A 26-year-old woman without prior psychiatric history was hospitalized for an acute psychotic episode. Treatment was initiated with quetiapine (25 mg at bedtime), and blonanserin (8 mg\/day) was added on the fifth hospital day to accelerate symptom control. On the fourth day of combination therapy, the patient developed symmetrical, erythematous papules limited to the dorsal and palmar aspects of both hands, with no history of new topical exposures. Although the rash was initially managed as dyshidrotic eczema or contact dermatitis with antihistamines and potent topical corticosteroids, it worsened over the following week. Given the strong temporal relationship, blonanserin was discontinued on the tenth day after rash onset, while quetiapine was continued. A dramatic improvement was observed within 72 hours, with near-complete resolution within one week. The patient\u2019s psychiatric symptoms remained stable on quetiapine monotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This is the first report of a bilateral hand-limited drug eruption due to blonanserin and underscores that prompt withdrawal upon rash appearance is important for patient comfort and aligns with good clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpsyt.2026.1751750","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T06:56:21Z","timestamp":1772693781000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Bilateral hand-restricted drug eruption induced by blonanserin: a case report"],"prefix":"10.3389","volume":"17","author":[{"given":"Liang","family":"Lv","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng-Yun","family":"Guan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2018.10.010","article-title":"Cutaneous adverse drug reactions to psychotropic drugs and their risk factors - a case-control study","volume":"29","author":"Greil","year":"2019","journal-title":"Eur Neuropsychopharmacol"},{"key":"B2","article-title":"Cutaneous side effects due to psychiatric drugs","volume":"19","author":"Rebok","year":"2008","journal-title":"Vertex"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200203090-00005","article-title":"Adverse cutaneous reactions to antipsychotics","volume":"3","author":"Warnock","year":"2002","journal-title":"Am J Clin Dermatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.08m04563","article-title":"Cutaneous adverse reactions to psychotropic drugs: data from a multicenter surveillance program","volume":"70","author":"Lange-Asschenfeldt","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"B5","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s12888-023-04598-y","article-title":"Effectiveness and safety of blonanserin in young and middle-aged female patients with schizophrenia: data from a post-marketing surveillance","volume":"23","author":"Bo","year":"2023","journal-title":"BMC Psychiatry"},{"key":"B6","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jphs.2020.09.006","article-title":"Safety and effectiveness of oral blonanserin for schizophrenia: A review of Japanese post-marketing surveillances","volume":"145","author":"Inoue","year":"2021","journal-title":"J Pharmacol Sci"},{"key":"B7","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2165\/11202620-000000000-00000","article-title":"Blonanserin: a review of its use in the management of schizophrenia","volume":"24","author":"Deeks","year":"2010","journal-title":"CNS Drugs"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0000000000001062","article-title":"Antipsychotic-induced drug rash with eosinophilia and systemic symptoms syndrome: A case report","volume":"28","author":"Gica","year":"2021","journal-title":"Am J Ther"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyy004","article-title":"Comparison of dopamine D3 and D2 receptor occupancies by a single dose of blonanserin in healthy subjects: A positron emission tomography study with [11C]-(+)-PHNO","volume":"21","author":"Tateno","year":"2018","journal-title":"Int J Neuropsychopharmacol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2022.10.005","article-title":"Drug hypersensitivity reactions","volume":"43","author":"Wilkerson","year":"2023","journal-title":"Immunol Allergy Clin North Am"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2011.11.014","article-title":"Psychiatric medications: adverse cutaneous drug reactions","volume":"31","author":"Bliss","year":"2013","journal-title":"Clin Dermatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.4103\/0378-6323.148566","article-title":"Drug eruptions induced by allopurinol associated with HLA-B*5801","volume":"81","author":"Zeng","year":"2015","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200140070-00003","article-title":"Clinical pharmacokinetics of quetiapine: an atypical antipsychotic","volume":"40","author":"DeVane","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"B15","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1124\/jpet.123.001767","article-title":"Gene polymorphisms and drug-drug interactions determine the metabolic profile of blonanserin","volume":"388","author":"Ye","year":"2024","journal-title":"J Pharmacol Exp Ther"},{"key":"B16","doi-asserted-by":"publisher","first-page":"5","DOI":"10.5070\/D397D8T291","article-title":"Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome","volume":"8","author":"Ghislain","year":"2002","journal-title":"Dermatol Online J"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1751750\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T06:56:22Z","timestamp":1772693782000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1751750\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,5]]},"references-count":16,"alternative-id":["10.3389\/fpsyt.2026.1751750"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2026.1751750","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,5]]},"article-number":"1751750"}}